Yap P L
Edinburgh and South East Scotland Blood Transfusion Service, Scotland.
Blut. 1990 Jan;60(1):8-14. doi: 10.1007/BF01720196.
Viral and bacterial infections are a serious cause of morbidity and mortality in patients immunocompromised as a result of malignancy, burns, trauma, viral infections or chemotherapy. The development of safe and effective antibody preparations suitable for intravenous use have transformed the lives of patients suffering from forms of primary immunodeficiency characterised by antibody deficiency. However, the role of intravenous immunoglobulin (IV IgG) preparations in the treatment of secondary immunodeficiencies is less clear and although many anecdotal reports exist for the use of IV IgG in various secondary immunodeficiencies (Table 1), there have been few controlled trials of a sufficient size that have demonstrated clear-cut efficacy in many of the suggested new indications.
病毒和细菌感染是导致因恶性肿瘤、烧伤、创伤、病毒感染或化疗而免疫功能低下患者发病和死亡的严重原因。适合静脉注射使用的安全有效抗体制剂的研发改变了患有以抗体缺乏为特征的原发性免疫缺陷患者的生活。然而,静脉注射免疫球蛋白(IV IgG)制剂在继发性免疫缺陷治疗中的作用尚不清楚,尽管有许多关于IV IgG用于各种继发性免疫缺陷的轶事报道(表1),但很少有足够规模的对照试验在许多建议的新适应症中证明有明确疗效。